MX2021005636A - Vesículas extracelulares modificadas y sus usos. - Google Patents
Vesículas extracelulares modificadas y sus usos.Info
- Publication number
- MX2021005636A MX2021005636A MX2021005636A MX2021005636A MX2021005636A MX 2021005636 A MX2021005636 A MX 2021005636A MX 2021005636 A MX2021005636 A MX 2021005636A MX 2021005636 A MX2021005636 A MX 2021005636A MX 2021005636 A MX2021005636 A MX 2021005636A
- Authority
- MX
- Mexico
- Prior art keywords
- exosomes
- protein
- therapeutic
- proteins
- exosome
- Prior art date
Links
- 210000001808 exosome Anatomy 0.000 abstract 10
- 108090000623 proteins and genes Proteins 0.000 abstract 7
- 102000004169 proteins and genes Human genes 0.000 abstract 7
- 238000000034 method Methods 0.000 abstract 5
- 230000001225 therapeutic effect Effects 0.000 abstract 4
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente descripción hace referencia a exosomas terapéuticos enriquecidos en proteínas que están presentes en la superficie luminal de los exosomas. La presente descripción proporciona métodos para fabricar exosomas enriquecidos en proteínas que están presentes en la superficie luminal de los exosomas, un método para asociar una proteína o péptido terapéutico a la superficie luminal de los exosomas y métodos de uso, por ejemplo, métodos de uso diagnóstico o terapéutico. Los métodos de fabricación implican generar exosomas modificados en la superficie luminal que incluyen una o más de la VE, por ejemplo, proteínas del exosoma en concentraciones mayores que las que se observan en exosomas de tipo salvaje, una modificación o un fragmento de la VE, por ejemplo, proteína del exosoma o una proteína de fusión de la VE, por ejemplo, proteína del exosoma y una carga útil, por ejemplo, una molécula activa desde un punto de vista biológico tal como un proteína terapéutica.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2018/061679 WO2019099942A1 (en) | 2017-11-17 | 2018-11-16 | Compositions of engineered exosomes and methods of loading luminal exosomes payloads |
| US201962835430P | 2019-04-17 | 2019-04-17 | |
| PCT/US2019/033629 WO2020101740A1 (en) | 2018-11-16 | 2019-05-22 | Engineered extracellular vesicles and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021005636A true MX2021005636A (es) | 2021-07-06 |
Family
ID=70732111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021005636A MX2021005636A (es) | 2018-11-16 | 2019-05-22 | Vesículas extracelulares modificadas y sus usos. |
Country Status (27)
| Country | Link |
|---|---|
| EP (2) | EP3672614B1 (es) |
| JP (1) | JP2022513049A (es) |
| KR (1) | KR20210098473A (es) |
| CN (1) | CN113286603A (es) |
| AU (1) | AU2019378591A1 (es) |
| BR (1) | BR112021009231A2 (es) |
| CA (1) | CA3119720A1 (es) |
| CL (1) | CL2021001278A1 (es) |
| CY (1) | CY1124897T1 (es) |
| DK (1) | DK3672614T3 (es) |
| EA (1) | EA202191334A1 (es) |
| ES (1) | ES2907967T3 (es) |
| HR (1) | HRP20220020T1 (es) |
| HU (1) | HUE057300T2 (es) |
| IL (1) | IL283167A (es) |
| LT (1) | LT3672614T (es) |
| MA (1) | MA49971B1 (es) |
| MD (1) | MD3672614T2 (es) |
| MX (1) | MX2021005636A (es) |
| PH (1) | PH12021551088A1 (es) |
| PL (1) | PL3672614T3 (es) |
| PT (1) | PT3672614T (es) |
| RS (1) | RS62863B1 (es) |
| SG (1) | SG11202104956QA (es) |
| SI (1) | SI3672614T1 (es) |
| TW (1) | TW202038993A (es) |
| WO (1) | WO2020101740A1 (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021020668A2 (pt) * | 2019-04-17 | 2022-01-11 | Codiak Biosciences Inc | Composições de exossomos e aav |
| EP3994158A1 (en) | 2019-07-03 | 2022-05-11 | Codiak BioSciences, Inc. | Extracellular vesicles targeting t cells and uses thereof |
| US20230018254A1 (en) | 2019-08-14 | 2023-01-19 | Codiak Biosciences, Inc. | Extracellular vesicles with antisense oligonucleotides targeting kras |
| BR112022002690A2 (pt) | 2019-08-14 | 2022-08-23 | Codiak Biosciences Inc | Construtos de vesícula-aso extracelular tendo como alvo cebp/beta |
| JP2022544934A (ja) | 2019-08-14 | 2022-10-24 | コディアック バイオサイエンシーズ， インコーポレイテッド | Ｓｔａｔ３－アンチセンスオリゴヌクレオチドを含む細胞外小胞 |
| WO2021030776A1 (en) * | 2019-08-14 | 2021-02-18 | Codiak Biosciences, Inc. | Extracellular vesicle-aso constructs targeting stat6 |
| WO2021062057A1 (en) | 2019-09-25 | 2021-04-01 | Codiak Biosciences, Inc. | Exogenous loading of exosomes via lyophilization |
| EP4034247A1 (en) | 2019-09-25 | 2022-08-03 | Codiak BioSciences, Inc. | Sting agonist comprising exosomes for treating neuroimmunological disorders |
| US20220395465A1 (en) | 2019-09-25 | 2022-12-15 | Codiak Biosciences, Inc. | Sting agonist comprising exosomes combined with il-12 displaying exosomes for treating a tumour |
| US20230103726A1 (en) | 2019-09-25 | 2023-04-06 | Codiak Biosciences, Inc. | Methods of producing extracellular vesicles |
| AU2020355240A1 (en) | 2019-09-25 | 2022-04-21 | Lonza Sales Ag | Extracellular vesicle compositions |
| US20230096378A1 (en) | 2020-03-12 | 2023-03-30 | Institute For Basic Science | Composition for inducing apoptosis of cells having genomic sequence variation and method for inducing apoptosis of cells by using composition |
| WO2021184020A1 (en) | 2020-03-13 | 2021-09-16 | Codiak Biosciences, Inc. | Methods of treating neuroinflammation |
| WO2021184021A1 (en) | 2020-03-13 | 2021-09-16 | Codiak Biosciences, Inc. | Extracellular vesicle-aso constructs targeting pmp22 |
| WO2021184017A1 (en) | 2020-03-13 | 2021-09-16 | Codiak Biosciences, Inc. | Extracellular vesicles for treating neurological disorders |
| WO2021189047A2 (en) | 2020-03-20 | 2021-09-23 | Codiak Biosciences, Inc. | Extracellular vesicles for therapy |
| WO2021248133A1 (en) | 2020-06-05 | 2021-12-09 | Codiak Biosciences, Inc. | Anti-transferrin extracellular vesicles |
| WO2022032140A2 (en) * | 2020-08-07 | 2022-02-10 | Amicus Therapeutics, Inc. | Vesicle targeting proteins and uses of same |
| WO2022066883A1 (en) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Extracellular vesicles comprising kras antigens and uses thereof |
| WO2022066928A2 (en) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Process for preparing extracellular vesicles |
| WO2022066934A2 (en) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Process for preparing extracellular vesicles |
| GB202015399D0 (en) * | 2020-09-29 | 2020-11-11 | Evox Therapeutics Ltd | Engineered extracellular vesicles displaying enhanced pharmacokinetics |
| US20230364127A1 (en) | 2020-10-06 | 2023-11-16 | Codiak Biosciences, Inc. | Extracellular vesicle-aso constructs targeting stat6 |
| CN112410304A (zh) * | 2020-11-12 | 2021-02-26 | 天津大学 | 一种基因修饰的外泌体及其制备方法和应用 |
| CN112899307A (zh) * | 2021-01-28 | 2021-06-04 | 苏州大学 | GluN1和/或GluN2亚基羧基末端豆蔻酰化的NMDA受体的应用 |
| JP2024506712A (ja) | 2021-02-17 | 2024-02-14 | ロンザ セールス アーゲー | 細胞外ベシクルを負荷する方法 |
| KR20230147125A (ko) * | 2021-02-17 | 2023-10-20 | 론자 세일즈 아게 | 세포외 소포-nlrp3 길항제 |
| IL305873A (en) | 2021-04-01 | 2023-11-01 | Lonza Sales Ag | Extracellular vesicle compositions |
| CN114057893B (zh) * | 2021-04-26 | 2022-12-30 | 苏州大学 | 一种编码线粒体定位的豆蔻酰化多肽及其制备方法与应用 |
| CN117126886A (zh) * | 2022-05-20 | 2023-11-28 | 谛邈生物科技(北京)有限公司 | 一种实现工程化EVs功能蛋白模块化装载的核酸构建体及其应用 |
| KR20230165196A (ko) * | 2022-05-24 | 2023-12-05 | 주식회사 시프트바이오 | 표면-개질된 세포외 소포체 및 이의 치료학적 용도 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| JP5718648B2 (ja) * | 2008-02-22 | 2015-05-13 | エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ（エイ・スター） | 間葉系幹細胞粒子 |
| FR2950350B1 (fr) | 2009-09-24 | 2013-12-13 | Centre Nat Rech Scient | Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations |
| US10501733B2 (en) * | 2015-02-27 | 2019-12-10 | University Of Washington | Polypeptide assemblies and methods for the production thereof |
| WO2017117585A1 (en) * | 2015-12-30 | 2017-07-06 | The Regents Of The University Of California | Methods for enhanced production and isolation of cell-derived vesicles |
| US10617768B2 (en) * | 2016-07-12 | 2020-04-14 | Santa Clara University | Engineered exosomes for the delivery of bioactive cargo using transmembrane tetraspanins |
| WO2018039119A1 (en) * | 2016-08-22 | 2018-03-01 | Codiak Biosciences, Inc. | Methods of suppressing delivery of exosomes to liver and spleen |
| WO2018112154A1 (en) * | 2016-12-15 | 2018-06-21 | Codiak Biosciences, Inc. | Methods of measuring exosomes using intrinsic fluorescence |
| MX2020001790A (es) | 2017-08-25 | 2020-07-22 | Codiak Biosciences Inc | Preparacion de exosomas terapeuticos mediante el uso de proteinas de membrana. |
| CN111511384A (zh) * | 2017-11-17 | 2020-08-07 | 科迪亚克生物科学公司 | 工程化外来体的组合物和负载腔外来体有效负载物的方法 |
| EP3841112A1 (en) * | 2018-08-24 | 2021-06-30 | Codiak BioSciences, Inc. | Extracellular vesicles targeting dendritic cells and uses thereof |
-
2019
- 2019-05-22 EP EP19731027.9A patent/EP3672614B1/en active Active
- 2019-05-22 ES ES19731027T patent/ES2907967T3/es active Active
- 2019-05-22 RS RS20220009A patent/RS62863B1/sr unknown
- 2019-05-22 CA CA3119720A patent/CA3119720A1/en active Pending
- 2019-05-22 SG SG11202104956QA patent/SG11202104956QA/en unknown
- 2019-05-22 JP JP2021526563A patent/JP2022513049A/ja active Pending
- 2019-05-22 LT LTEPPCT/US2019/033629T patent/LT3672614T/lt unknown
- 2019-05-22 HU HUE19731027A patent/HUE057300T2/hu unknown
- 2019-05-22 DK DK19731027.9T patent/DK3672614T3/da active
- 2019-05-22 BR BR112021009231-5A patent/BR112021009231A2/pt unknown
- 2019-05-22 MA MA49971A patent/MA49971B1/fr unknown
- 2019-05-22 MX MX2021005636A patent/MX2021005636A/es unknown
- 2019-05-22 WO PCT/US2019/033629 patent/WO2020101740A1/en unknown
- 2019-05-22 AU AU2019378591A patent/AU2019378591A1/en active Pending
- 2019-05-22 MD MDE20200694T patent/MD3672614T2/ro unknown
- 2019-05-22 PL PL19731027T patent/PL3672614T3/pl unknown
- 2019-05-22 HR HRP20220020TT patent/HRP20220020T1/hr unknown
- 2019-05-22 SI SI201930182T patent/SI3672614T1/sl unknown
- 2019-05-22 CN CN201980083366.0A patent/CN113286603A/zh active Pending
- 2019-05-22 PT PT197310279T patent/PT3672614T/pt unknown
- 2019-05-22 EP EP21200884.1A patent/EP4059510A1/en active Pending
- 2019-05-22 KR KR1020217018358A patent/KR20210098473A/ko active Search and Examination
- 2019-05-22 EA EA202191334A patent/EA202191334A1/ru unknown
- 2019-05-23 TW TW108117910A patent/TW202038993A/zh unknown
-
2021
- 2021-05-11 PH PH12021551088A patent/PH12021551088A1/en unknown
- 2021-05-13 IL IL283167A patent/IL283167A/en unknown
- 2021-05-14 CL CL2021001278A patent/CL2021001278A1/es unknown
-
2022
- 2022-01-07 CY CY20221100020T patent/CY1124897T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA202191334A1 (ru) | 2022-02-10 |
| WO2020101740A9 (en) | 2021-06-10 |
| TW202038993A (zh) | 2020-11-01 |
| SG11202104956QA (en) | 2021-06-29 |
| CY1124897T1 (el) | 2023-01-05 |
| WO2020101740A1 (en) | 2020-05-22 |
| HRP20220020T1 (hr) | 2022-04-01 |
| BR112021009231A2 (pt) | 2021-08-10 |
| CN113286603A (zh) | 2021-08-20 |
| SI3672614T1 (sl) | 2022-04-29 |
| DK3672614T3 (da) | 2022-01-10 |
| CL2021001278A1 (es) | 2022-03-11 |
| JP2022513049A (ja) | 2022-02-07 |
| MA49971B1 (fr) | 2022-01-31 |
| PT3672614T (pt) | 2022-02-11 |
| HUE057300T2 (hu) | 2022-05-28 |
| MA49971A (fr) | 2020-07-01 |
| EP3672614A1 (en) | 2020-07-01 |
| IL283167A (en) | 2021-06-30 |
| EP4059510A1 (en) | 2022-09-21 |
| MD3672614T2 (ro) | 2022-04-30 |
| CA3119720A1 (en) | 2020-05-22 |
| RS62863B1 (sr) | 2022-02-28 |
| LT3672614T (lt) | 2022-04-11 |
| ES2907967T3 (es) | 2022-04-27 |
| AU2019378591A1 (en) | 2021-06-17 |
| KR20210098473A (ko) | 2021-08-10 |
| EP3672614B1 (en) | 2021-10-06 |
| PL3672614T3 (pl) | 2022-03-07 |
| PH12021551088A1 (en) | 2022-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021551088A1 (en) | Engineered extracellular vesicles and uses thereof | |
| AR115159A1 (es) | Vesículas extracelulares modificadas y usos de las mismas | |
| MX2019013752A (es) | Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr optimizado en codones. | |
| EP4036079A3 (en) | Compounds and compositions for intracellular delivery of agents | |
| EA202090919A1 (ru) | Липидные наночастицы для доставки модифицированной рнк, кодирующей полипептид vegf-a | |
| PH12018502538A1 (en) | Antibodies to alpha-synuclein and uses thereof | |
| PE20171336A1 (es) | Anticuerpos contra tau y sus usos | |
| MX2018015414A (es) | Terapia de célula t adoptiva mejorada. | |
| EP3192526A3 (en) | Exosomes for delivery of biotherapeutics | |
| CO6640254A2 (es) | Método para preparar anticuerpos con propiedades mejoradas | |
| EA201100070A1 (ru) | Туберкулезный белок rv2386c, композиции и их применения | |
| PE20170142A1 (es) | Proteina de fusion que inhibe angiogenesis o crecimiento y uso de la misma | |
| PH12019502036A1 (en) | Peptides and methods for the treatment of diabetes | |
| WO2018170150A3 (en) | Engraftable cell-based immunotherapy for long-term delivery of therapeutic proteins | |
| MX2014004132A (es) | Señuelos humanos notch1. | |
| SG10201805039UA (en) | Protease resistant peptides | |
| MX2022014077A (es) | Formulaciones y metodos para tratar organismos fotosinteticos y mejorar las calidades y cantidades de los rendimientos con formulaciones de compuestos de glicano. | |
| PH12020551955A1 (en) | Anti-cd63 antibodies, conjugates, and uses thereof | |
| NZ762312A (en) | Anti-pacap antibody | |
| EA201690826A1 (ru) | Рекомбинантные гликопротеиды и их применения | |
| MX2018016417A (es) | Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de las mismas. | |
| MX2021007444A (es) | Proteina biespecifica. | |
| WO2014039074A3 (en) | Therapeutic compositions and related methods | |
| WO2019087133A8 (en) | Method of treating tendinopathy using interleukin-17 (il-17) antagonists | |
| MX2018014716A (es) | Anticuerpos anti-tnfrsf25. |